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Neuroinflammation has been identified as a causative factor of multiple neurological
diseases. The nucleotide-binding oligomerization domain-, leucine-rich repeat- and
pyrin domain-containing 3 (NLRP3) inflammasome, a subcellular multiprotein complex
that is abundantly expressed in the central nervous system (CNS), can sense and be
activated by a wide range of exogenous and endogenous stimuli such as microbes,
aggregated and misfolded proteins, and adenosine triphosphate, which results in
activation of caspase-1. Activated caspase-1 subsequently leads to the processing
of interleukin-1β (IL-1β) and interleukin-18 (IL-18) pro-inflammatory cytokines and
mediates rapid cell death. IL-1β and IL-18 drive inflammatory responses through
diverse downstream signaling pathways, leading to neuronal damage. Thus, the
NLRP3 inflammasome is considered a key contributor to the development of
neuroinflammation. In this review article, we briefly discuss the structure and activation
the NLRP3 inflammasome and address the involvement of the NLRP3 inflammasome
in several neurological disorders, such as brain infection, acute brain injury and
neurodegenerative diseases. In addition, we review a series of promising therapeutic
approaches that target the NLRP3 inflammasome signaling including anti-IL-1 therapy,
small molecule NLRP3 inhibitors and other compounds, however, these approaches
are still experimental in neurological diseases. At present, it is plausible to generate
cell-specific conditional NLRP3 knockout (KO) mice via the Cre system to investigate
the role of the NLRP3 inflammasome, which may be instrumental in the development of
novel pharmacologic investigations for neuroinflammation-associated diseases.
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INTRODUCTION
Neuroinflammation is a fundamental innate immune response in the central nervous system (CNS)
by which the brain and spinal cord react to diverse pathogens and host-derived signals of cellular
damage. Inflammatory responses are necessary steps for eliminating invading agents, clearing
damaged cells and promoting tissue repair (Miwa et al., 1997; Tahara et al., 2006; Ito et al., 2007;
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Ribes et al., 2009; Szretter et al., 2009); however, uncontrolled
neuroinflammation may lead to further tissue injury and neural
dysfunction (Lazovic et al., 2005; Choi et al., 2009; Abo-Ouf et al.,
2013). Therefore, it has become evident that neuroinflammation
represents a significant cause of neurological deficits.
Researchers have recently focused their attention on a
group of subcellular multiprotein complexes referred to as
inflammasomes (Martinon et al., 2002), whose formation
and activation may be induced by a wide range of substances
(Kanneganti et al., 2006b; Mariathasan et al., 2006; Martinon
et al., 2006; Sutterwala et al., 2007; Newman et al., 2010;
Rathinam et al., 2010). In particular, the nucleotide-binding
oligomerization domain-, leucine-rich repeat- and pyrin
domain-containing 3 (NLRP3) inflammasome has gained
considerable attention (Agostini et al., 2004). It is abundantly
expressed in the CNS and may serve to detect noxious agents or
irregularities in the cellular microenvironment (Halle et al., 2008;
Yin et al., 2009; Jha et al., 2010; Geldhoff et al., 2013b; Yang et al.,
2014). Activated NLRP3 inflammasome leads to the activation
of caspase-1, which mediates the production of interleukin-1β
(IL-1β) and interleukin-18 (IL-18) pro-inflammatory cytokines
and the initiation of a rapid form of cell death termed pyroptosis
(Martinon et al., 2002; Kanneganti et al., 2006a; Fink et al.,
2008). IL-1β and IL-18, in turn, initiate multiple signaling
pathways and drive inflammatory responses, which results
in neuronal injury or death (Yatsiv et al., 2002; Bossù et al.,
2010; Meissner et al., 2010; Wilms et al., 2010). Therefore, the
NLRP3 inflammasome plays a crucial role in the development
of inflammatory responses in the CNS. Moreover, emerging
studies have revealed the involvement of NLRP3 signaling in
several neurological disorders (Gris et al., 2010; Hoegen et al.,
2011; Fann et al., 2013b; Heneka et al., 2013; Johann et al.,
2015).
Herein, we describe the general principles involved
in the structure and activation mechanisms of the
NLRP3 inflammasome in the CNS, as well as the complex
neuroinflammatory signaling pathways and consequences
associated with NLRP3 inflammasome activation under
the circumstances of brain infection, acute injury and
neurodegenerative disorders. Finally, we conclude that
NLRP3 inflammasome signaling may represent a promising
therapeutic target for the treatment of neuroinflammation-
associated neurological diseases.
MICROGLIA AND ASTROCYTES IN
NEUROINFLAMMATION
Emerging evidence supports the notion that various
pathological changes within the CNS elicit a prominent
inflammatory reaction referred to as neuroinflammation.
In the CNS parenchyma, microglia and astrocytes are
the primary effectors of neuroinflammation (Karve et al.,
2016; Shrivastava et al., 2017). Plasma membrane pattern
recognition receptors (PRRs) expressed on glial cells play
an important role in the activation of nuclear factor-κB
(NF-κB) and mitogen-activated protein kinase inflammatory
pathways (Tang et al., 2013; Heneka et al., 2014). In addition,
microglial-astrocyte communication is highly important in CNS
innate immunity.
Microglia, the resident macrophage-like cells of the CNS,
are derived from yolk-sac myeloid progenitors during the
early stage of embryonic development (Kierdorf et al., 2013).
They continually monitor and survey their assigned brain
regions and participate in CNS development, neuroprotection,
and the maintenance of hemostasis (Paolicelli et al., 2012;
Nayak et al., 2014). Microglia express numerous PRRs that
are responsible for the early recognition of pathogen-associated
molecular patterns (PAMPs) and damage-associated molecular
patterns (DAMPs), such as Toll-like receptors (TLRs), NOD-like
receptors (NLRs), retinoic acid-inducible gene-I-like receptors
and triggering receptor expression on myeloid cells 2 (TREM2;
Shah et al., 2008; Kumar et al., 2011; Hu et al., 2012; Fu et al.,
2014). Microglial cells are considered the earliest responders
to pathological insults on the CNS (Becher et al., 2000; Saijo
et al., 2013). Under non-pathological conditions, microglial
cells have a highly ramified appearance. Upon detecting
environmental challenges, such as brain injury, infection, or
protein aggregates, microglia become rapidly ‘‘activated’’ and
transform to an ameboid appearance with increased expression
of major histocompatibility complex molecules and other
markers (Rock et al., 2004; Kettenmann et al., 2011). Proliferation
and migration of microglial cells also occur (Byrnes and
Faden, 2007). Moderate microglial responses exert protective
effects on the CNS in some circumstances (Lalancette-Hébert
et al., 2007). Nevertheless, over-activated microglia can lead to
neuroinflammation, oxidative stress and neuronal dysfunction
due to the excess production of a wide range of cytotoxic
factors, such as tumor necrosis factor-α (TNF-α), IL-1β, IL-18,
IL-6, reactive oxygen species (ROS) and nitric oxide (NO;
Moss and Bates, 2001; Heneka and O’Banion, 2007; Nayak
et al., 2014). Moreover, the interaction between microglia
and other immune cells results in secondary inflammatory
responses. Recent findings have involved microglia activation in
the initiation and maintenance of inflammatory responses in the
context of infectious brain diseases, acute CNS injury and several
neurodegenerative diseases (Aoki et al., 2009; Fellner et al., 2013;
Elmore et al., 2014; Liu et al., 2015; Kumar et al., 2016; Li D. et al.,
2016; Xian et al., 2016).
Similar to peripheral macrophages, several broad
classifications of microglia M1, M2a, M2b and M2c have
been identified in the literature (Geissmann et al., 2010;
Franco and Fernández-Suárez, 2015). ‘‘Classically activated’’
M1 microglia, which exhibit an ameboid appearance, strong
phagocytic capability and high mobility, are characterized by the
generation and secretion of large amounts of pro-inflammatory
mediators and high levels of oxidative production (Loane and
Byrnes, 2010; Zhang et al., 2016). Generally, ‘‘alternatively
activated’’ M2 microglia exhibit a hyper-ramification appearance
(Cherry et al., 2014) and produce plenty of anti-inflammatory
cytokines, neurotrophic factors, and extracellular matrix
molecules (David and Kroner, 2011; Michell-Robinson et al.,
2015). Therefore, M2 microglia are primarily associated with the
resolution of inflammation and tissue repair. Three subclasses of
M2 microglia exhibit slight differences in cellular markers and
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functions. M2b microglia are characterized by large amounts of
pro-inflammatory cytokine generation and by high IL-10 and
low IL-12 expression (Ferrante et al., 2013; Orihuela et al., 2016),
which allows them to be able to shift to a mixture of M1 and
M2a/b.
Substantial numbers of astrocytes are present in the CNS
parenchyma, and they perform a diverse array of functions
including glutamate uptake, fuel provision, synaptogenesis,
structural support and immune defense (Brown and Ransom,
2007; Perea et al., 2009, 2014; Barreto et al., 2011). Astrocytes
display a great degree of heterogeneity in their morphology,
lineage, anatomical locations and gene expression profile
(Zhang and Barres, 2010; Sosunov et al., 2014). Astrocytes
are equipped with various innate immune receptors, and
they directly respond to different types of CNS insults
with hypertrophy and hyperplasia, a process referred to
as astrogliosis. Astrocytes, however, are involved in the
formation of compact astrocytic scars by forming and orienting
long processes toward the core of severely damaged sites
(Cregg et al., 2014). Under normal circumstances, reactive
astrogliosis and scar formation are essential for confining
CNS inflammation to the lesion epicenter, protecting neural
networks and promoting repair of the blood–brain barrier (BBB;
Pekny and Nilsson, 2005; Sofroniew, 2005, 2009). However,
under pathological conditions, astrogliosis can interfere with
neurite growth and regeneration (Silver and Miller, 2004;
Anderson et al., 2014; Cregg et al., 2014). Moreover, reactive
astrocytes produce numerous pro-inflammatory mediators,
such as cytokines, chemokines and NO, which makes them
essential for exacerbating inflammatory responses. Notably, by
regulating specific signaling events, astrogliosis can exert either
potent pro-inflammatory effects or essential anti-inflammatory
effects.
NLRP3 INFLAMMASOME
The NLRP3 inflammasome was first characterized in Muckle-
Wells Autoinflammatory Disorder (Martinon et al., 2002;
Agostini et al., 2004). NLRP3 inflammasome can sense various
stimuli and form a molecular platform for caspase-1 activation,
which leads to the processing and release of IL-1β and IL-18
and eventually potentiates inflammatory responses that are
involved in multiple infectious, inflammatory and immune
diseases (Sutterwala et al., 2006; Willingham et al., 2007;
Halle et al., 2008; Masters et al., 2010; Walsh et al., 2014).
Thus, the NLRP3 inflammasome is of crucial importance in
the development of both acute and chronic inflammatory
responses.
The NLRP3 inflammasome mainly consists of a cytosolic
sensor molecule NLRP3, an adaptor protein apoptosis-associated
speck-like protein containing a caspase activating recruitment
domain (ASC), and a cysteine protease pro-caspase-1 as the
effector molecule (Agostini et al., 2004; see Figure 1).
NLRP3 contains a C-terminal leucine-rich repeat (LRR)
domain, a conserved central nucleotide binding and
oligomerization domain (NOD or NACHT), and an N-terminal
pyrin-only domain (PYD; Anderson et al., 2004). The LRR
domain recognizes PAMPs and other ligands, maintains the
NLRP inactive state, and mediates protein-protein interactions
(Meng et al., 2003; O’Connor et al., 2003; Hoffman et al., 2010).
The NACHT domain, with ATPase activity, is essential for
protein self-oligomerization during the inflammasome assembly
FIGURE 1 | NLRP3 inflammasome: structure and function. The NLRP3 inflammasome mainly consists of the cytosolic sensor molecule NLRP3, the adaptor
protein ASC, and the effector molecule pro-caspase-1. The assembly and activation of NLRP3 inflammasome results in caspase-1 activation. Activated caspase-1
subsequently leads to the maturation of IL-1β and IL-18, as well as mediates a form of inherent inflammatory cell death termed as pyroptosis. ASC, apoptosis-related
speck-like protein containing a caspase recruitment domain; CARD, caspase activation and recruitment domain; GSDMD, gasdermin D; GSDMD-NT, gasdermin-N
domain of GSDMD; IL, interleukin; LRR, leucine-rich repeat; NACHT (NOD), nucleotide binding and oligomerization domain; NLRP3, nucleotide-binding
oligomerization domain-, leucine-rich repeat- and pyrin domain-containing 3; PYD, pyrin-only domain.
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process (Duncan et al., 2007). The PYD enables protein-protein
homotypic interactions between NLRP and the bipartite adapter
ASC (Liepinsh et al., 2003).
ASC consists of an N-terminal PYD and a C-terminal
caspase activation and recruitment domain (CARD; Masumoto
et al., 1999). ASC binds to the upstream NLRP3 through a
homotypic PYD-PYD domain interaction, which results in ASC
dimer assembly into a large speck-like structure (Dowds et al.,
2004). ASC interacts with pro-casapase-1 via the CARD domain
(Srinivasula et al., 2002).
Caspase-1 is present as a catalytically inactive precursor pro-
caspase-1 in unstimulated cells. Pro-caspase-1 recruitment,
which is mediated by ASC, contributes to caspase-1
oligomerization and auto-proteolytic conversion of the
pro-enzyme into its active form (Agostini et al., 2004). The
active caspase-1 fragments elicit the maturation and secretion
of pro-inflammatory cytokines IL-1β and IL-18, which belong
to the IL-1β family and mediate subsequent immune responses
(Keller et al., 2008).
Caspase-1 activation also induces a form of inherent
inflammatory cell death, referred to as pyroptosis, which
is characterized by rapid plasma-membrane rupture, DNA
fragmentation, and the release of pro-inflammatory cytosolic
contents into the extracellular space (Bergsbaken et al., 2009).
Pyroptosis is both morphologically and mechanistically different
from apoptosis and other forms of cell death. Recent studies
have identified that activated caspase-1 cleaves gasdermin D
(GSDMD) to generate the gasdermin-N domain of GSDMD
(GSDMD-NT), which can directly bind phosphoinositides and
cardiolipin (Shi J. et al., 2015; Ding et al., 2016; Liu et al.,
2016). GSDMD-NT then associates with the plasma membrane
and oligomerizes to form non-selective pores, which triggers
cell swelling and lysis (Chen et al., 2016; Liu et al., 2016). Both
neurons and glial cells may trigger this process of cell death in
response to a wide range of pathological stimuli (Adamczak et al.,
2014; Tan et al., 2014; Kim et al., 2015).
ACTIVATION AND REGULATION OF THE
NLRP3 INFLAMMASOME
The NLRP3 inflammasome is the most extensively investigated
inflammasome, and it is present in microglia and astrocytes in
the CNS (Cho et al., 2014; Lu et al., 2014; Zendedel et al., 2016).
It remains debated whether neurons express NLRP3 (Fann et al.,
2013a; Yang et al., 2014; Kaushal et al., 2015). In vitro studies
suggest that the basal level of NLRP3 in resting cells is not
sufficient to activate the inflammasome. It is widely accepted
that successful NLRP3 inflammasome activation requires a
two-checkpoint signal process. A priming signal is provided by
the NF-κB-activating stimuli to transcriptionally enhance the
expression of NLRP3 and pro-IL-1β (Bauernfeind et al., 2009).
Many TLR and NLR ligands, as well as endogenous cytokines
such as IL-1α, have been demonstrated to prime cells. The
subsequent activating signal is provided by various NLRP3-
activating agents to promote the formation of the inflammasome
complex. A wide range of exogenous and endogenous stimuli
including PAMPs, aggregated and misfolded proteins, ATP and
crystalline substances induce NLRP3 activation (Mariathasan
et al., 2006; Martinon et al., 2006; Halle et al., 2008; Demento
et al., 2009; Duncan et al., 2009; Shi F. et al., 2012).
Given the broad array of NLRP3 activators, NLRP3 appears
to sense the disturbance of cellular homeostasis rather than
directly react to these stimuli. To elucidate this, researchers
have proposed several theories as follows: (1) low intracellular
K+ concentration may play a major role in common signal
transduction for NLRP3 activation (Pétrilli et al., 2007; Marina-
García et al., 2008; Karmakar et al., 2016); (2) endo-lysosomal
destabilization induces the release of cathepsins into the
cytosol, which may directly activate NLRP3 (Hornung et al.,
2008; Sharp et al., 2009; Bruchard et al., 2013); (3) ROS,
mitochondrial DNA and phospholipid cardiolipin released from
damaged mitochondria activate NLRP3 (Zhou et al., 2010, 2011;
Subramanian et al., 2013); (4) Ca2+ flux and the Ca2+-dependent
signaling trigger the assembly of NLRP3 inflammasome (Feske
et al., 2012; Lee et al., 2012; Murakami et al., 2012).
The activity of NLRP3 is finely regulated through distinct
mechanisms. Recent studies have revealed that BRCC-3, double-
stranded RNA-dependent protein kinase, death-associated
protein kinase 1 and Bruton’s tyrosine kinase function as
endogenous positive regulators of NLRP3 inflammasome activity
(Chuang et al., 2011; Juliana et al., 2012; Lu et al., 2012; Py et al.,
2013; Ito et al., 2015). A member of the NIMA-related kinase
(NEK) family, NEK7 has been shown to directly bind to the LRR
domain of NLRP3 and act downstream of K+ efflux and ROS
generation to promote the assembly of NLRP3 inflammasome
(He et al., 2016; Schmid-Burgk et al., 2016; Shi et al., 2016).
Nevertheless, autophagy, microRNAs, CARD-only proteins,
pyrin-only proteins and NO act as endogenous negative
regulators of NLRP3 (Saitoh et al., 2008; Hernandez-Cuellar
et al., 2012; Shi C. S. et al., 2012; Mishra et al., 2013; de Almeida
et al., 2015; Qin et al., 2015; Yang et al., 2015).
EFFECTS OF INFLAMMASOME
ACTIVATION ON NEUROINFLAMMATION
The NLRP3/caspase-1/IL-1 axis has emerged as a critical
signaling pathway of the innate immune system in
the CNS (Rosenzweig et al., 2011; see Figure 2). The
abundance of caspase-1 has been identified in the context
of neuroinflammation-related disorders (Sifringer et al., 2007; de
Rivero Vaccari et al., 2016). IL-1β and IL-18 are cytokines that
are matured by the NLRP3 inflammasome. The involvement of
IL-1β and IL-18 in neuroinflammation has long been speculated
(Arend et al., 2008; Dinarello et al., 2012). High levels of
IL-1β and IL-18 have been demonstrated in the cerebrospinal
fluid (CSF), brain tissue and plasma of patients with CNS
infection, brain injury and neurodegenerative diseases such as
Alzheimer’s disease (AD) and multiple sclerosis (MS; Licastro
et al., 2000; de Jong et al., 2002; Huang et al., 2004). Both IL-1β
and IL-18 bind to their respective receptors on microglial cells,
astrocytes, neurons and endothelial cells, thereby triggering
a complex spectrum of signaling events, which results in
secondary expression of multiple inflammation-associated
genes. Notably, cytokine-mediated processes were shown to be
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FIGURE 2 | NLRP3 inflammasome activation-mediated neuroinflammation. Upon activation by a wide range of exogenous and endogenous stimuli, the
NLRP3 inflammasome located in microglia and astrocytes trigger the maturation of IL-1β and IL-18 and induce pyroptotic cell death. The high levels IL-1β and IL-18
bind to their receptors on glial cells, neurons, macrophages and endothelial cells, as well as cooperate with other cytokines to initiate Th-cell signaling, thereby
triggering a complex spectrum of signaling events, which results in exacerbation of inflammatory cascade responses within the central nervous system (CNS).
Aβ, β-amyloid; ATP, adenosine triphosphate; BBB, blood–brain barrier; IL, interleukin; MSU, monosodium urate; NF-κB, nuclear factor-κB; NLRP3,
nucleotide-binding oligomerization domain-, leucine-rich repeat- and pyrin domain-containing 3; Th, T helper.
involved in cognitive decline and have been verified to lead to
long-term neuropsychiatric disorders (McAfoose and Baune,
2009).
IL-1β signaling plays a major role in the initiation and
continuation of the inflammatory reactions in the CNS in
response to various adverse stimuli (Cannon, 2000). IL-1β
contributes to modulating the integrity of the BBB, which
results in the infiltration of peripheral immune cells into
the CNS (Alvarez et al., 2011). IL-1β also stimulates the
activation of microglia and astrocytes, which in turn activates
CNS-infiltrated T cells and induces the generation of additional
pro-inflammatory factors such as IL-6 and TNF-α, as well as
neurotoxic mediators (Ferrari et al., 2004). Moreover, IL-1β
indirectly recruits leukocytes by augmenting the expression of
chemokines (Gosselin and Rivest, 2007). Several experimental
studies have even demonstrated that over-expression of IL-1β
mediates neuronal injury by regulating glutamate excitotoxicity
(Hu et al., 2000; Fogal et al., 2007).
IL-18 mainly stimulates T-helper (Th) cell-mediated immune
responses by inducing the production of adhesion molecules,
pro-inflammatory cytokines and chemokines in natural killer,
Th1 and B cells (Nakahira et al., 2002; Bossù et al., 2010). IL-18
also activates signaling pathways in microglia, which results in
increased caspase-1 expression and matrix metalloproteinases
and pro-inflammatory cytokine production (Felderhoff-Mueser
et al., 2005). In addition, IL-18 augments Fas ligand expression in
glial cells, thereby exacerbating Fas-mediated neuronal cell death
in the context of neuroinflammation. IL-18 thus converges two
distinct immunological regulatory pathways of inflammatory
reactions and cytotoxic effects.
Pyroptosis is a highly inflammatory, programmed form of cell
death. It is distinct from necrosis and apoptosis as the pathway
is exclusively mediated by activated caspase-1 (Bergsbaken et al.,
2009). So far, pyroptosis has been described in both glial
cells and neurons (Alfonso-Loeches et al., 2014; Tan et al.,
2014; Kim et al., 2015). Pyroptosis causes rapid rupture of the
plasma membrane and excessive release of pro-inflammatory
cytokines and chemokines such as TNF-α, IL-1β, IL-6 and
CX3C-chemokine ligand 3, which may aggravate inflammatory
mediator-induced neuronal death (Fink et al., 2008; Ramesh
et al., 2013). As these factors have been shown to mediate the
recruitment of other immune cells from peripheral circulation,
plenty of leukocytes are attracted to the inflammation sites,
and the subsequent inflammatory responses cause severe tissue




Aberrant activation of NLRP3 inflammasome signaling has been
demonstrated to contribute to pathology in a broad spectrum of
neurological diseases (see Table 1).
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TABLE 1 | Neurological disorders that involve the NLRP3 inflammasome.
Disease Current animal models Reference
Brain infection S. pneumoniae meningitis Intracisternal inoculation of S. pneumoniae strain (mouse) Hoegen et al. (2011), Geldhoff et al.
(2013a), Kim et al. (2015)
Japanese encephalitis Intravenous injection of Japanese Encephalitis virus (mouse) Kaushik et al. (2012)
Influenza virus infection Intranasal infection of influenza virus (mouse) Yu et al. (2014)
HIV/AIDS Feline immunodeficiency virus infection (cat); HIV-1 Vpr
transgenic mouse
Mamik et al. (2016)
Acute injury Cerebral ischemia Focal cerebral ischemia: transient middle cerebral artery
occlusion (mouse, rat); global cerebral ischemia: bilateral
4-vessel occlusion (rat)
Fann et al. (2013b), Yang et al. (2014),
Wang et al. (2015), Thakkar et al. (2016)
Traumatic brain injury Modified Feeney model (mouse); controlled cortical impact
(rat); Blast-induced traumatic brain injury (rat)
Liu et al. (2013), Ma et al. (2016), Lin
et al. (2017)
Spinal cord injury Dorsal root avulsion (rat); spinal cord contusion lesion (rats) Ellis et al. (2016), Jiang et al. (2016),
Zendedel et al. (2016)
Subarachnoid hemorrhage Endovascular perforation model (rat) Li J. et al. (2016), Shao et al. (2016)
Intracerebral hemorrhage Autologous blood injection (mouse) Ma et al. (2014), Yang et al. (2015)
Neurodegenerative
diseases
Alzheimer’s disease APP/PS1 mouse; TgCRND8 AD mouse; 3xTgAD mouse;
stereotaxic injection of β-amyloid
Heneka et al. (2013), Cho et al. (2014),
Liu et al. (2015), Daniels et al. (2016),
Dempsey et al. (2017)
Multiple sclerosis Experimental autoimmune encephalitis Jha et al. (2010), Inoue et al. (2012),
Coll et al. (2015)
Amyotrophic lateral sclerosis SOD1(G93A) mouse model Johann et al. (2015), Debye et al. (2016)
Prion diseases (remains controversial) Prion inoculation (mouse) Nuvolone et al. (2015)
Brain Infection
Bacterial infection
Streptococcus pneumoniae (S. pneumoniae) causes meningitis
when it invades the CSF space. Studies of both murine models
and patients have demonstrated that the NLRP3 inflammasome
plays a central role in the pathologic progression of
pneumococcal meningitis (Hoegen et al., 2011; Geldhoff
et al., 2013a). Pneumolysin, a pneumococcal pore-forming
cytolysin, induced caspase-1-dependent pyroptotic cell death
and IL-1β maturation through ATP-dependent lysosomal
destabilization and ROS production (Kim et al., 2015). Excessive
NLRP3 inflammasome activation led to extensive inflammatory
responses and exacerbated tissue damage in the brain, as
well as other adverse outcomes (Wu et al., 2010; Hoegen
et al., 2011; Mitchell et al., 2012). Staphylococcus aureus
(S. aureus) also induced NLRP3 inflammasome activation in
microglia in an ATP- and cathepsin B-dependent manner
(Hanamsagar et al., 2011). Moreover, priming microglia with
conditioned media from Mycobacterium tuberculosis (Mtb)-
infected macrophages, in combination with infection with
Mtb, instigated robust activation of the NLRP3 inflammasome.
Lowering intracellular K+ concentrations, lysosomal protease
release and mitochondrial ROS generation were suggested to
be upstream events of Mtb-induced NLRP3 activation (Lee
et al., 2013). Listeria monocytogenes (LM) is the causative
agent of several life-threatening diseases, including meningitis
and septicemia (Roed et al., 2012; Thønnings et al., 2016). As
NLRP3 is one of the major sensors of LM (Warren et al., 2008),
it is plausible that NLRP3 inflammasome play a role in the
pathology of LM-associated meningitis.
Viral Infection
Japanese Encephalitis virus (JEV) represents a common cause
of acute viral encephalitis. Microglia rapidly respond to JEV
infection and secrete several pro- and anti-inflammatory
cytokines, including IL-1β and IL-18. JEV triggers
NLRP3 inflammasome activation through K+ efflux and
ROS production, as shown in a murine model and Bv-2
microglial cells (Kaushik et al., 2012). It has been implicated
that NLRP3 inflammasome signaling plays a crucial role in host
protection during influenza virus challenge; however, prolonged
NLRP3 inflammasome activation induces a hyper-inflammatory
state and contributes to pathogenesis and mortality (Thomas
et al., 2009; McAuley et al., 2013; Pinar et al., 2016; Tate et al.,
2016). Additionally, the expression of NLRP3 was up-regulated
in murine brains during influenza viral infection (Yu et al.,
2014). Interestingly, the expression of NLRP3 inflammasome-
associated genes was also increased in the brains of patients
with HIV/AIDS (Walsh et al., 2014). An in vivo model of
feline immunodeficiency viral infection and HIV-1 Vpr
transgenic mice exhibited NLRP3 inflammasome activation with
accompanying neuronal loss and neurological disorders (Walsh
et al., 2014; Mamik et al., 2016).
CNS Injury
Cerebral Ischemia
The innate immune response plays a critical role in the overall
pathogenesis of cerebral ischemia injury. Inflammatory cytokines
released from activated microglia initiate downstream signaling
cascades that eventually lead to neuronal cell loss following
acute brain ischemia (Harari and Liao, 2010). NLRP3 protein
was found to increase after experimental ischemic stroke,
which was concomitant with high IL-1β and IL-18 levels and
extensive neuronal and glial cell death (Lammerding et al., 2016).
Interference of NLRP3 activation improved cerebral ischemia
outcomes, as evidenced by reduced infarction volumes and
decreased levels of neurovascular damage (Fann et al., 2013b;
Yang et al., 2014).
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Traumatic Injury
Traumatic brain injury (TBI) and spinal cord injury (SCI)
are both debilitating conditions worldwide and are associated
with poor prognosis (Levin and Diaz-Arrastia, 2015; Witiw and
Fehlings, 2015). In general, they result from insults by an external
mechanical force (Xiong et al., 2013), which is characterized by
both primary and secondary injury mechanisms. The primary
injury is the immediate mechanical disruption of brain tissue.
The secondary injury triggers cascades of cellular and molecular
events over a prolonged time course (Werner and Engelhard,
2007; Ji et al., 2012). IL-1β has been widely implicated in
the progression of TBI and SCI. The protein levels of the
NLRP3 inflammasome components were increased in TBI and
SCI patients and in murine models (Adamczak et al., 2012; Liu
et al., 2013; Zendedel et al., 2016). Notably, ASC neutralization
substantially reduced the contusion volume in a rat model of TBI
(de Rivero Vaccari et al., 2009). Pannexin1 channel, in addition
to being linked to activation of the NLRP3 inflammasome, serves
as a cell death effector during neuronal pyroptosis, which makes
it a potential therapeutic target (Adamczak et al., 2014).
Hemorrhagic Stroke
Intracerebral hemorrhage (ICH) is a devastating stroke subtype
(Keep et al., 2012). The pathophysiology of ICH is characterized
by the infiltration of systemic immune cells, the activation of
microglia and the production of pro-inflammatory cytokines
such as IL-1β (Wang and Doré, 2007). The expression
of NLRP3 was increased in a mouse model of ICH, and
the inhibition of NLRP3 attenuated neuroinflammation and
improved neuronal function, which indicates the involvement
of NLRP3 inflammasome in the pathogenesis of ICH (Ma
et al., 2014; Yang et al., 2015; Yuan et al., 2015). ROS and the
P2X purinergic receptor 7 (P2X7R) pathway may play roles in
NLRP3 activation during ICH (Ma et al., 2014; Feng et al., 2015).
Subarachnoid hemorrhage (SAH) is a fatal cerebrovascular
disease with the highest mortality among all stroke subtypes
(Bian et al., 2012; Keep et al., 2012). Early brain injury,
which is highlighted by neuroinflammation, represents a
key mechanism of SAH development (Sehba et al., 2012).
NLRP3 inflammasome was found to be activated in a rat SAH
model (Li J. et al., 2016; Shao et al., 2016). Pharmacological
inhibition of P2X7R ameliorated brain edema and neurological
deficits, which indicates a mechanism of the P2X7R pathway in
NLRP3 activation after SAH (Chen et al., 2013).
Neurodegenerative Diseases
Neurodegenerative diseases are always accompanied by
chronic neuroinflammation with the excessive production
of IL-1β and IL-18 pro-inflammatory cytokines, which has
detrimental consequences for brain structure and function.
The NLRP3 inflammasome is of particular importance in the
development of inflammatory responses. To date, a pathogenic
role of the NLRP3 inflammasome has been shown in several
neurodegenerative diseases including AD, MS and amyotrophic
lateral sclerosis (ALS). Whether the NLRP3 inflammasome
contributes to the pathogenesis of Prion diseases remains
debated.
AD
The expression of NLRP3 and caspase-1 is substantially
increased in the brains of AD patients (Heneka et al., 2013;
Saresella et al., 2016). It has become evident that extracellular
deposition of β-amyloid (Aβ) peptides in senile plaques is
the initiating event in AD. Aβ drives the release of mature
IL-1β via activation of the NLRP3 inflammasome in microglia
(Halle et al., 2008; Parajuli et al., 2013). NLRP3 or caspase-1
deficiency substantially attenuates spatial memory impairment
and enhances Aβ clearance in AD transgenic mice (Heneka
et al., 2013). According to a candidate gene study conducted
among northern Han Chinese, two functional single-nucleotide
polymorphisms (SNPs) in the NLRP3 gene (rs2027432 and
rs10754558) had synergistic effects on late-onset AD risk
(Tan et al., 2013). Moreover, CARD8 protein suppresses
NLRP3 activity, and another study indicates that the p.C10X
polymorphism of the CARD8 gene (rs2043211) predisposes
people to AD (Fontalba et al., 2008).
MS
MS is characterized by the demyelination of axons and chronic
inflammation; experimental autoimmune encephalitis (EAE) is
the most widely used rodent model for MS. The expression levels
of caspase-1, IL-1β and IL-18 were increased in MS plaques
and cells from MS patients (Huang et al., 2004; Inoue et al.,
2012). NLRP3-deficient mice exhibited resistance to EAE, as
evidenced by reduced demyelination and astrogliosis in the
spinal cord (Gris et al., 2010). It has been suggested that the
NLRP3 inflammasome is likely involved in EAE pathogenesis
through the induction of chemokine-mediated recruitment of
immune cells (Inoue et al., 2012). However, recent studies have
shown that pertussis toxin, which is commonly injected as an
adjuvant to increase EAE incidence, induced activation of a
pyrin-dependent inflammasome (Dumas et al., 2014; Barclay and
Shinohara, 2017), Therefore, the inflammasome sensor involved
in MS/EAE might be not restricted to NLRP3.
ALS
Mutations in human superoxide dismutase 1 lead to the
formation of toxic misfolded protein aggregates, which play an
important role in the pathogenesis ALS (Tsuda et al., 1994;
Ioannides et al., 2016). Increased NLRP3, ASC, IL-1β, IL-18
and active caspase-1 levels were detected in both human ALS
tissue and in murine models (Johann et al., 2015; Debye
et al., 2016). Transactive response DNA-binding protein-43
(TDP-43) is considered a major component of intraneuronal
aggregates in ALS patients (Arai et al., 2006). TDP-43 instigated
NLRP3 inflammasome activation in microglia, which resulted
in a pro-inflammatory signaling that is detrimental to motor
neurons (Zhao et al., 2015).
Prion Diseases
Prion diseases are caused by the conversion of cellular prion
protein (PrPC) to the pathological isoform PrPSc through
conformational changes (Shi F. et al., 2015). Aggregated PrPSc
peptides lead to the activation of microglia and astrocytes,
which results in the release of pro-inflammatory cytokines
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and neurotoxic factors (Tribouillard-Tanvier et al., 2009). PrP
exposure up-regulated NLRP3 and ASC expression in microglia,
and silencing of NLRP3 or ASC significantly reduced IL-1β
production (Shi F. et al., 2012). However, a recent in vivo study
using NLRP3- or ASC-deficient mice inoculated with scrapie
prions demonstrated that NLRP3 and ASC were not involved
in prion pathogenesis (Nuvolone et al., 2015). This discrepancy
might be attributed to the different prion proteins used in these
studies and the strain-specific features of prion diseases (Tixador
et al., 2010; Ayers et al., 2011). More studies on other forms
of prion diseases are needed to verify the involvement of the
NLRP3 inflammasome.
TARGETING THE NLRP3 INFLAMMASOME
FOR THE TREATMENT OF
NEUROLOGICAL DISEASES
The relevance of the NLRP3 inflammasome in human
CNS pathologies has led to research on the possibilities of
pharmacologically targeting the NLRP3 signaling pathways. To
date, several advances have been made in the identification of
exogenous compounds that may block IL-1 signaling or serve
as inhibitors of NLRP3 inflammasome activation (White et al.,
2017; see Figure 3); however, most compounds are in the early
stages of development.
Anti-IL-1 Therapy
Currently, anti-IL-1 therapies including interleukin-1 receptor
antagonists (IL-1Ra) such as anakinra and specific monoclonal
antibodies such as canakinumab have been approved for use
in patients with auto-inflammatory disorders (Kuemmerle-
Deschner et al., 2011). IL-1Ra administration reduced ischemic
brain injury in a murine stroke model; however, it failed
to exhibit long-term beneficial effects (Paolicelli et al.,
2012). Anakinra is thought to have a preponderance for
cryopyrin-associated periodic syndrome (CAPS)-associated
neurologic disease because of its better CNS penetration.
In addition, several other applications that target IL-1 or
IL-1R are also under development (Dinarello et al., 2012).
Despite their notable efficacy, anti-IL-1 drugs cannot resolve
inflammasome-associated symptoms. Nevertheless, caspase-
1-mediated pathways such as pyroptosis also drive disease
pathology. These findings suggest that the direct blockade
of inflammasome activation instead of merely neutralizing
its downstream cytokines may be advantageous for controlling
unwanted inflammatory reactions. Moreover, anti-IL-1 therapies
are expensive and most of themmay not readily penetrate tissues
such as the brain.
Small Molecule Inhibitors of NLRP3
Compounds with a sulfonylurea moiety appear to specifically
inhibit activation of the NLRP3 inflammasome in the activation
FIGURE 3 | Therapeutic approaches to targeting the NLRP3 inflammasome. The cartoon depicts the schematic mode of various therapeutic approaches
described in detail in the text. Several steps in NLRP3 activation and the IL-1 pathway have been identified as targets for anti-neuroinflammatory therapies.
ASC, apoptosis-related speck-like protein containing a caspase recruitment domain; ATP, adenosine triphosphate; BBG, brilliant blue G; BHB, β-hydroxybutyrate;
IL, interleukin; IL-1R, interleukin-1 receptor; MNS, 3,4-methylenedioxy-β-nitrostyrene; NF-κB, nuclear factor-κB; NLRP3, nucleotide-binding oligomerization domain-,
leucine-rich repeat- and pyrin domain-containing 3; P2X7R, P2X purinergic receptor 7; TLR, Toll-like receptor.
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stage without affecting the NF-κB signaling-dependent priming
stage (Lamkanfi et al., 2009; Coll et al., 2015). Glyburide
was the first identified sulfonylurea moiety-containing drug
to exhibit NLRP3-inhibitory activity in vitro; however, the
required in vivo dose is associated with hypoglycemic effects.
MCC950, a small-molecule compound that shares similarities
with sulfonylurea, was shown to block ASC oligomerization
induced by NLRP3, which makes it a highly potent and selective
NLRP3 inhibitor. It effectively attenuated the inflammatory
response in murine EAE models and ex vivo human samples
(Coll et al., 2015). Its role in other neurological diseases
requires additional investigation. Additionally, 16673-34-0, an
intermediate substrate in glyburide synthesis, exhibited no effect
on glucose metabolism and has been demonstrated to ameliorate
myocardial ischemia/reperfusion (I/R) injury by inhibiting the
formation of the NLRP3 inflammasome (Marchetti et al.,
2014).
The ketone metabolite β-hydroxybutyrate (BHB) was
discovered to suppress NLRP3 inflammasome activation by
inhibiting NLRP3-ASC oligomerization (Youm et al., 2015).
Experiments showed that BHB decreased K+ efflux and
endoplasmic reticulum stress (Youm et al., 2015; Bae et al.,
2016). Furthermore, BHB is transported to brain parenchyma
and plays a neuroprotective role under several pathological
conditions (Orhan et al., 2015; Xie et al., 2015).
A cysteinyl leukotriene receptor antagonist, which had been
initially incorrectly termed as CRID3, was found to prevent
caspase-1 activation in response to NLRP3 activators via direct
inhibition of ASC oligomerization (Coll et al., 2011, 2015).
INF4E is a newly synthesized compound that directly
inhibits NLRP3 ATPase and specifically suppresses
NLRP3 inflammasome activation (Cocco et al., 2014). It
was shown to be protective against NLRP3-involved myocardial
I/R in a rat model (Mastrocola et al., 2016). Further rigorous
investigations are needed to evaluate the effects of INF4E on
neurological diseases and its side effects.
3,4-methylenedioxy-β-nitrostyrene (MNS), a novel tyrosine
kinase inhibitor, was reported to specifically and potently inhibit
NLRP3 by directly targeting its NOD and LRR domain (He
and Amer, 2014). According to a recent study, MNS prevented
wound progression and improved healing in an experimental
burn model (Xiao et al., 2016). The potent effects and minimal
cytotoxicity of MNS make it an attractive candidate for the
treatment of neurological diseases; however, studies investigating
the role of MNS in the CNS are lacking (Hsieh et al.,
2010).
Other Compounds that Target Specific
Pathways
Artemisinin, a well-established antimalarial drug, has been
verified to exert anti-inflammatory effects via inhibition of the
NF-κB signaling pathway. Artemisinin treatment also reduced
the neuritic plaque burden and NLRP3 inflammasome activity
in an AD transgenic mouse model (Shi et al., 2013). Studies
have shown that artemisinin induces various side effects such
as neurotoxicity, cardiotoxicity, embryotoxicity and allergic
reactions when administered long-term (Efferth and Kaina, 2010;
Li and Hickman, 2011).
The ATP-gated receptor P2X7R has been implicated in
activation of the NLRP3 inflammasome (Deplano et al., 2013).
P2X7R antagonist brilliant blue G (BBG) alleviated inflammation
and improved neurological functions in a rodent model of SAH
(Chen et al., 2013). BBG can penetrate the BBB at relatively
low doses (Diaz-Hernandez et al., 2012). However, the use of
P2X7R antagonists is controversial as these receptors are located
in various cell types under pathological conditions and they may
induce undesirable off-target effects (Franke et al., 2004).
Probenecid, an FDA-approved drug for gout and
hyperuricemia treatment, is a specific Pannexin1 channel blocker
(Silverman et al., 2009). Probenecid inhibited NLRP3 activation
in cultured neurons and astrocytes by providing a high
extracellular concentration of K+ and decreased caspase-1
expression in the brains of aged rats (Mawhinney et al., 2011;
Jian et al., 2016).
A recent study reported that fenamate non-steroidal
anti-inflammatory drugs (NSAIDs), including flufenamic acid
and mefenamic acid, were neuroprotective in rodent models
of AD (Daniels et al., 2016). Fenamates selectively inhibited
NLRP3 by blocking volume-regulated anion channels (VRAC)
in macrophages (Daniels et al., 2016). Fenamate NSAIDs
target both VRAC/NLRP3 and cyclooxygenases, which makes
them more efficacious than those targeting a single point
in one inflammatory pathway. However, fenamate NSAIDs
are associated with CNS toxicity, gastrointestinal adverse
effects, nephrotoxicity, metabolic acidosis and prolongation
of prothrombin time (Kingswell, 1981; Redmond, 1981; Frank
et al., 1983; Court and Volans, 1984; Kamour et al., 2016). It
is important to reassess the benefit-risk profile of fenamate
NSAIDs for treating NLRP3-associated disorders.
OUTSTANDING QUESTIONS
To date, several hurdles that require further investigation
remain. Because the mechanisms of NLRP3 activation are
differentially regulated at the cell and tissue levels (Toldo
et al., 2015), it is necessary to characterize each step of the
NLRP3 inflammasome cascades in specific cell types and brain
regions under different pathological contexts. Additionally, the
potential roles of NLRP3 signaling in the regulation of specific




Major advances in the understanding of inflammasomes
and inflammasome-mediated disorders have been made in
the past decade. A spectrum of inflammatory responses
has been associated with CNS pathological circumstances;
thus, inflammasome activation likely exerts strong influences
on various neurological diseases. Insufficient activation of
inflammasome causes the host to become vulnerable to PAMPs
and DAMPs; nevertheless, excessive inflammasome activation
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causes unfavorable outcomes in diverse diseases (Rathinam
et al., 2012). Thus, the manipulation of a balanced and
effective inflammasome-mediated inflammatory response is of
paramount importance.
Recent years, Cre-lox recombination-mediated neurogenetics
has been developed as a useful technique to generate cell-specific
gene knock-outs (KO) and knock-ins (Witten et al., 2011).
Conditional autophagy gene KO mice have been recently
generated by breeding autophagy-deficient mice with specific
Cre drivers to investigate the regulatory role of autophagy
in NLRP3 inflammasome activation in microglia (Cho et al.,
2014). It is plausible to generate microglia/astrocyte conditional
NLRP3 KO and knock-in mice through a similar genetic
approach to study cell-specific interactions.
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